THRM

Gentherm Inc. (THRM) | Rumor.io

Gentherm

THRM

Attention (50-day avg)0%

Attention rank (50-day avg)#2,207

Bullish sentiment (50-day avg)97%

Price to earnings ratio39.9

Market capitalization1B

Earnings per share0.86

Dividend yield (TTM)—

Revenue (annual)1.5B

Net income (annual)18.3M

Social

What share of all stock conversation is about THRM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% +0	0% 0

Jul 23

Gentherm Incorporated's Q2 2026 results exceeded expectations, with revenue up 11% YoY and EPS up 600% YoY.
The company raised its full-year guidance, expecting product revenues between $1.55B and $1.65B, adjusted EBITDA of $185M to $200M, and adjusted free cash flow of $85M to $100M.
Gentherm's stock price surged by ~19.3% to $43.01, and the company announced a new increased stock repurchase authorization.

Generated by AI

Sentiment

Of the messages about THRM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0%	0% -100	99.06% -0.04
Bearish	100%	100%	100% new	0.94% +0.04

Bullish· Jan 18

$THRM has achieved a 200% gain in approximately 31 days, with the potential for further growth.
The company's stock has shown significant momentum, with a 483% increase for one investor who has already locked in profits.
$THRM is on a tear, with a new ATH and a 73% increase in a single day, suggesting it has legs and may not be far off from reaching $1.

Bearish· Apr 23

The market flow is being manipulated by investors buying and selling shares to recover their short positions, potentially affecting THRM's price.
This activity is aimed at providing liquidity and supporting the price, rather than a genuine interest in the company.
The short covering could be a temporary boost, but it may not necessarily translate to long-term buying interest in THRM.

Generated by AI

Topics

Of the messages about THRM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	88.17%	62.85%
Technical Analysis	0%	0%	0%	25.3%
Earnings	0%	0%	0%	2.77%
Analysts	0%	0%	11.83%	7.91%
Macro	0%	0%	0%	1.19%
Controversies	0%	0%	0%	0%

Earnings· Mar 1

Gentherm Incorporated (THRM) reported earnings of $1.16, beating the consensus estimate of $0.64 and the Earnings Whisper estimate of $0.71.
The company's Q4 revenue of $288.88M also beat the estimate of $257.29M.
Gentherm guided FY21 revenue above consensus, with updated EPS and revenue guidance of $1.05-1.13 billion.

Announcements· Mar 31

Therma Bright has secured a major order for 1,750 units of its Venowave VW5 device from the DME Authority in Nashville, TN, which is expected to dominate the prevention of blood clots in the booming $4B+ global market.
The deal is seen as a game-changer, opening new avenues in health and propelling Therma Bright's entry into the $4B+ market, with the potential to cut recovery time in high-risk patients dramatically.
The strategic momentum from this order is expected to capitalize on the $3B compression market growth transforming vascular health, with Therma Bright poised for breakthrough as Venowave ramps up with major distribution.

Generated by AI

Community

Of the messages about THRM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	16.67%	1.32%	2.94%	2.97%
Newcomers	83.33%	98.68%	97.06%	97.03%

Regulars· Feb 22

Gentherm Incorporated (THRM) reported FQ4 earnings of 47c EPS and $343.32M in revenue, missing the Estimize EPS consensus by 20c and the Estimize revenue consensus by $4.31M.
The company filed an 8-K report on February 22, disclosing its 2022 fourth-quarter and full-year results, as well as providing a strategic update with a 2026 outlook.
Gentherm's Q4 2022 earnings call transcript is available, showing the company's revenue and EPS for the quarter, as well as the EPS and revenue for the full 2022 year.

Newcomers· Jan 21

Therma Bright's Venowave VW5 has secured a significant purchase order for 1,750 units valued at $1.434M from DME Authority, bringing both companies closer to market penetration.
The Venowave VW5 device is expected to dominate the compression therapy market, growing from $4.18B to $6.72B by 2033 at a 7.3% CAGR, with a potential $1B U.S. market and FDA 510k approval.
Therma Bright is gearing up for widespread U.S. entry with a key distribution deal, aiming to tap into a billion-dollar market and transform care for 900K+ U.S. patients with its FDA-approved blood circulation aid.

Generated by AI

News

JPMorgan Upgrades Gentherm to Overweight From Neutral, Price Target is $48

Gentherm (THRM) has an average rating of overweight and mean price target of $50, according to analy

15d agoYahoo Finance

Gentherm (THRM), Why Is Its Latest Update Drawing Attention?

Why Gentherm’s merger vote matters now Gentherm (THRM) just cleared a key hurdle for its planned merger with Modine’s Performance Technologies business, after shareholders approved more authorized common shares and backed the share issuance needed to close the deal. Gentherm’s share price has eased in the short term, with a 1-day move down 1.6%, a 7-day decline of 6.1% and a 30-day drop of 13.1%. However, the 90-day share price return of 7.6% and 1-year total shareholder return of 8.5% point...

15d agoYahoo Finance

Gentherm (THRM) Shareholders Approve Modine Merger, Clear for October Close

17d agoYahoo Finance

Also Discussed

Investors talking about THRM also mention

#	Name	Attention
1	HLTH - Cue Health Inc.	——
2	Healthpeak Properties, Inc.DOC	0.04%new
3	Gaia, Inc. Class A Common StockGAIA	0%0
4	MindWalk Holdings Corp.IPA	0%0
5	Matrix Service CompanyMTRX	0%0
6	Procaps Group S.A.PROC	0%0
7	CSTR - CapStar Financial Holdings, Inc.	——
8	Owens CorningOC	0%0
9	BorgWarner Inc.BWA	0%new
10	Greenland Technologies Holding Corp. Class AGTEC	0%new

Gentherm Inc.

Consumer Cyclical
Auto Parts

Gentherm Inc. is a global technology company that designs, develops, manufactures, and sells thermal management and pneumatic comfort solutions. The company focuses on products that regulate temperature and enhance comfort across automotive and medical applications, including climate control seats, climate control interiors, lumbar and massage comfort systems, valve systems, climate and comfort electronics, and patient temperature management systems. Its automotive portfolio supports vehicle seating, interiors, and related comfort features used by major original equipment manufacturers and Tier 1 suppliers. In medical markets, Gentherm provides temperature management technologies used in hospital and clinical settings. Headquartered in Novi, Michigan, Gentherm operates internationally and serves industries where precise thermal control, passenger comfort, and patient care are central product requirements.

Website

Location

28875 Cabot Drive

Northville, MI, 48377

United States

Social

What share of all stock conversation is about THRM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% +0	0% 0

Jul 23

Gentherm Incorporated's Q2 2026 results exceeded expectations, with revenue up 11% YoY and EPS up 600% YoY.
The company raised its full-year guidance, expecting product revenues between $1.55B and $1.65B, adjusted EBITDA of $185M to $200M, and adjusted free cash flow of $85M to $100M.
Gentherm's stock price surged by ~19.3% to $43.01, and the company announced a new increased stock repurchase authorization.

Generated by AI

Sentiment

Of the messages about THRM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	0%	0% -100	99.06% -0.04
Bearish	100%	100%	100% new	0.94% +0.04

Bullish· Jan 18

$THRM has achieved a 200% gain in approximately 31 days, with the potential for further growth.
The company's stock has shown significant momentum, with a 483% increase for one investor who has already locked in profits.
$THRM is on a tear, with a new ATH and a 73% increase in a single day, suggesting it has legs and may not be far off from reaching $1.

Bearish· Apr 23

The market flow is being manipulated by investors buying and selling shares to recover their short positions, potentially affecting THRM's price.
This activity is aimed at providing liquidity and supporting the price, rather than a genuine interest in the company.
The short covering could be a temporary boost, but it may not necessarily translate to long-term buying interest in THRM.

Generated by AI

Topics

Of the messages about THRM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	88.17%	62.85%
Technical Analysis	0%	0%	0%	25.3%
Earnings	0%	0%	0%	2.77%
Analysts	0%	0%	11.83%	7.91%
Macro	0%	0%	0%	1.19%
Controversies	0%	0%	0%	0%

Earnings· Mar 1

Gentherm Incorporated (THRM) reported earnings of $1.16, beating the consensus estimate of $0.64 and the Earnings Whisper estimate of $0.71.
The company's Q4 revenue of $288.88M also beat the estimate of $257.29M.
Gentherm guided FY21 revenue above consensus, with updated EPS and revenue guidance of $1.05-1.13 billion.

Announcements· Mar 31

Therma Bright has secured a major order for 1,750 units of its Venowave VW5 device from the DME Authority in Nashville, TN, which is expected to dominate the prevention of blood clots in the booming $4B+ global market.
The deal is seen as a game-changer, opening new avenues in health and propelling Therma Bright's entry into the $4B+ market, with the potential to cut recovery time in high-risk patients dramatically.
The strategic momentum from this order is expected to capitalize on the $3B compression market growth transforming vascular health, with Therma Bright poised for breakthrough as Venowave ramps up with major distribution.

Generated by AI

Community

Of the messages about THRM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	16.67%	1.32%	2.94%	2.97%
Newcomers	83.33%	98.68%	97.06%	97.03%

Regulars· Feb 22

Gentherm Incorporated (THRM) reported FQ4 earnings of 47c EPS and $343.32M in revenue, missing the Estimize EPS consensus by 20c and the Estimize revenue consensus by $4.31M.
The company filed an 8-K report on February 22, disclosing its 2022 fourth-quarter and full-year results, as well as providing a strategic update with a 2026 outlook.
Gentherm's Q4 2022 earnings call transcript is available, showing the company's revenue and EPS for the quarter, as well as the EPS and revenue for the full 2022 year.

Newcomers· Jan 21

Therma Bright's Venowave VW5 has secured a significant purchase order for 1,750 units valued at $1.434M from DME Authority, bringing both companies closer to market penetration.
The Venowave VW5 device is expected to dominate the compression therapy market, growing from $4.18B to $6.72B by 2033 at a 7.3% CAGR, with a potential $1B U.S. market and FDA 510k approval.
Therma Bright is gearing up for widespread U.S. entry with a key distribution deal, aiming to tap into a billion-dollar market and transform care for 900K+ U.S. patients with its FDA-approved blood circulation aid.

Generated by AI

Gentherm

Social

Jul 23

Bullish· Jan 18

Bearish· Apr 23

Earnings· Mar 1

Announcements· Mar 31

Regulars· Feb 22

Newcomers· Jan 21

Are Investors Undervaluing Gentherm (THRM) Right Now?

Stifel reiterates Gentherm stock buy rating on acquisition update

Gentherm Declares Special Cash Dividend Payable After Completion of Modine Deal

JPMorgan Upgrades Gentherm to Overweight From Neutral, Price Target is $48

Gentherm (THRM), Why Is Its Latest Update Drawing Attention?

Gentherm (THRM) Shareholders Approve Modine Merger, Clear for October Close

Also Discussed

Gentherm Inc.

Company Information

Location

Are Investors Undervaluing Gentherm (THRM) Right Now?

Stifel reiterates Gentherm stock buy rating on acquisition update

Gentherm Declares Special Cash Dividend Payable After Completion of Modine Deal

JPMorgan Upgrades Gentherm to Overweight From Neutral, Price Target is $48

Gentherm (THRM), Why Is Its Latest Update Drawing Attention?

Gentherm (THRM) Shareholders Approve Modine Merger, Clear for October Close

Also Discussed

Social

Jul 23

Bullish· Jan 18

Bearish· Apr 23

Earnings· Mar 1

Announcements· Mar 31

Regulars· Feb 22

Newcomers· Jan 21